2762 Reboxetine Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine. 98769-81-4 65856 C19H23NO3 313.167790 White powder. 170-171°C (Mesylate salt) 8 mg/mL (Mesylate salt) Reboxetine is rapidly and extensively absorbed following oral administration. Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake <i>in vitro</i> to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low <i>in vivo</i> and <i>in vitro</i> affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors. Reboxetine is metabolized by dealkylation, hydroxylation and oxidation followed by glucuronide or sulphate conjugation. It is metabolized by the cytochrome P450 CYP isoenzyme 3A4. Half Life: 12.5 hours No indication of carcinogenicity to humans (not listed by IARC). For the treatment of clinical depression. Reports of seizures (rare) have been reported 2009-07-21T20:26:21Z 2014-12-24T20:25:50Z Reboxetine 402799 Reboxetine DB00234 true [H][C@](OC1=CC=CC=C1OCC)(C1=CC=CC=C1)[C@]1([H])CNCCO1 C19H23NO3 InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1 InChIKey=CBQGYUDMJHNJBX-OALUTQOASA-N 313.3908 313.167793607 Exogenous Solid 3.1 HMDB14379 CHEMBL14370 59268